Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gynecologic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Lung Neoplasms 1Liver Neoplasms 1Esophageal Neoplasms 1Colonic Neoplasms 1Breast Neoplasms 1

Interventions

Docetaxel 43enzalutamide 31Prednisone 25Abiraterone Acetate 24Magnetic Resonance Spectroscopy 18abiraterone 15pembrolizumab 14bicalutamide 14Radiotherapy 14Cyclophosphamide 13darolutamide 12Leuprolide 12Goserelin 12apalutamide 10Ipilimumab 10olaparib 9Specimen Handling 9Radiosurgery 9Radiation 9Injections 9Biopsy 9Pluvicto 8Paclitaxel 8Radiotherapy, Intensity-Modulated 7Carboplatin 7sargramostim 6fludarabine 6cabazitaxel 6Sirolimus 6Nivolumab 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Prostatic Neoplasms × NP-G2-044 × Clear all
NCT03199586 2025-07-20

Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Treatment-Refractory Solid Tumor Malignancies

Novita Pharmaceuticals, Inc.

Phase 1 Completed
23 enrolled
BreastGastrointestinalGenitourinaryGynecologicThoracic

Breast Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Liver Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡